Tags

Type your tag names separated by a space and hit enter

Development of colon targeted drug delivery systems for mebendazole.
J Control Release. 2001 Nov 09; 77(1-2):87-95.JC

Abstract

The objective of the present study is to develop colon targeted drug delivery systems for mebendazole using guar gum as a carrier. Matrix tablets containing various proportions of guar gum were prepared by wet granulation technique using starch paste as a binder. The tablets were evaluated for drug content uniformity, and were subjected to in vitro drug release studies. The amount of mebendazole released from the matrix tablets at different time intervals was estimated by a high-performance liquid chromatography method. Guar gum matrix tablets released 8-15% of the mebendazole in the physiological environment of stomach and small intestine depending on the proportion of guar gum used in the formulation. When the dissolution study was continued in simulated colonic fluids the matrix tablets containing 20% of guar gum released another 83% of mebendazole after degradation into 2-3 pieces. The matrix tablets containing 30% of guar gum also released about 50% of mebendazole in simulated colonic fluids indicating the susceptibility of the guar gum formulations to the rat caecal contents. The results of the study show that matrix tablets containing either 20% or 30% of guar gum are most likely to provide targeting of mebendazole for local action in the colon. The mebendazole matrix tablets containing either 20% or 30% of guar gum showed no change either in physical appearance, drug content or dissolution pattern after storage at 45 degrees C/75% relative humidity for 3 months. Differential scanning calorimetry indicated no possibility of interaction between mebendazole and guar gum.

Authors+Show Affiliations

Pharmaceutical Technology Division, Department of Pharmaceutical Sciences, College of Engineering, Andhra University, Visakhapatnam 530 003, India. krishnaysr112@rediffmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11689262

Citation

Krishnaiah, Y S., et al. "Development of Colon Targeted Drug Delivery Systems for Mebendazole." Journal of Controlled Release : Official Journal of the Controlled Release Society, vol. 77, no. 1-2, 2001, pp. 87-95.
Krishnaiah YS, Veer Raju P, Dinesh Kumar B, et al. Development of colon targeted drug delivery systems for mebendazole. J Control Release. 2001;77(1-2):87-95.
Krishnaiah, Y. S., Veer Raju, P., Dinesh Kumar, B., Bhaskar, P., & Satyanarayana, V. (2001). Development of colon targeted drug delivery systems for mebendazole. Journal of Controlled Release : Official Journal of the Controlled Release Society, 77(1-2), 87-95.
Krishnaiah YS, et al. Development of Colon Targeted Drug Delivery Systems for Mebendazole. J Control Release. 2001 Nov 9;77(1-2):87-95. PubMed PMID: 11689262.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development of colon targeted drug delivery systems for mebendazole. AU - Krishnaiah,Y S, AU - Veer Raju,P, AU - Dinesh Kumar,B, AU - Bhaskar,P, AU - Satyanarayana,V, PY - 2001/11/2/pubmed PY - 2002/1/10/medline PY - 2001/11/2/entrez SP - 87 EP - 95 JF - Journal of controlled release : official journal of the Controlled Release Society JO - J Control Release VL - 77 IS - 1-2 N2 - The objective of the present study is to develop colon targeted drug delivery systems for mebendazole using guar gum as a carrier. Matrix tablets containing various proportions of guar gum were prepared by wet granulation technique using starch paste as a binder. The tablets were evaluated for drug content uniformity, and were subjected to in vitro drug release studies. The amount of mebendazole released from the matrix tablets at different time intervals was estimated by a high-performance liquid chromatography method. Guar gum matrix tablets released 8-15% of the mebendazole in the physiological environment of stomach and small intestine depending on the proportion of guar gum used in the formulation. When the dissolution study was continued in simulated colonic fluids the matrix tablets containing 20% of guar gum released another 83% of mebendazole after degradation into 2-3 pieces. The matrix tablets containing 30% of guar gum also released about 50% of mebendazole in simulated colonic fluids indicating the susceptibility of the guar gum formulations to the rat caecal contents. The results of the study show that matrix tablets containing either 20% or 30% of guar gum are most likely to provide targeting of mebendazole for local action in the colon. The mebendazole matrix tablets containing either 20% or 30% of guar gum showed no change either in physical appearance, drug content or dissolution pattern after storage at 45 degrees C/75% relative humidity for 3 months. Differential scanning calorimetry indicated no possibility of interaction between mebendazole and guar gum. SN - 0168-3659 UR - https://www.unboundmedicine.com/medline/citation/11689262/Development_of_colon_targeted_drug_delivery_systems_for_mebendazole_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0168365901004618 DB - PRIME DP - Unbound Medicine ER -